Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology

Objective: This study was conducted to examine the effects of front-line chemotherapy on overall survival (OS) and postrecurrence survival (PRS) of patients with recurrent ovarian cancer, when stratifying the histologic type. Methods: Five hundred and seventy-four patients with recurrent ovarian can...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gynecologic oncology 2014-01, Vol.25 (1), p.43
Main Authors: Hiroaki Kajiyama, Kiyosumi Shibata, Mika Mizuno, Tomokazu Umezu, Shiro Suzuki, Ryuichiro Sekiya, Kaoru Niimi, Hiroko Mitsui, Eiko Yamamoto, Michiyasu Kawai, Tetsuro Nagasaka, Fumitaka Kikkawa
Format: Article
Language:Korean
Subjects:
Chemotherapy
Histologic type
Overall survival
Postrecurrence survival
Recurrent ovarian cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: This study was conducted to examine the effects of front-line chemotherapy on overall survival (OS) and postrecurrence survival (PRS) of patients with recurrent ovarian cancer, when stratifying the histologic type. Methods: Five hundred and seventy-four patients with recurrent ovarian cancer with sufficient clinical information, including front-line chemotherapy, were analyzed. The pathologic slides were evaluated by central pathologic review. The patients were divided into two groups: group A (n=261), who underwent taxane plus platinum, and group B (n=313), who underwent conventional platinum-based chemotherapy without taxanes. Results: The median age was 54 years (range, 14 to 89 years). Group A had significantly better median OS (45.0 months vs. 30.3 months, p
ISSN:2005-0380